Figure 6
Addition of ICOS antibody to radiation and anti-PD1 on overall survival in the anti-PD1 immunotherapy resistant Panc02 tumor model. (a) (i) Experimental design. 2 × 105 Panc02 cells were implanted subcutaneously into the flanks of C57Bl/6 mice on day 0. On day 14 all mice in radiation groups were treated with 12 Gy radiation to the tumor using CT guidance. Mice were injected i.p. with 0.25 mg/kg ICOS antibody or in control groups, mice were treated with equivalent dose of isotype control antibody on day 14 and day 21. For mice in groups receiving PD1 antibody, mice were injected i.p. with 250 µg PD1 antibody on day 7, day 14 and day 21. (ii) Average tumor growth curves for mice treated as in (i). (iii) Overall survival curves for mice treated as in (i). Statistics key for panel (a) (iii): ****p < 0.0001, ***p < 0.001, as determined by Log-rank test. N = 10 mice per group and experiments were repeated at least 2x.
